Head to Head Survey: Madrigal Pharmaceuticals (NASDAQ:MDGL) and VistaGen Therapeutics (NASDAQ:VTGN)

VistaGen Therapeutics (NASDAQ:VTGN) and Madrigal Pharmaceuticals (NASDAQ:MDGL) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, institutional ownership and valuation.

Institutional and Insider Ownership

78.4% of VistaGen Therapeutics shares are owned by institutional investors. Comparatively, 98.5% of Madrigal Pharmaceuticals shares are owned by institutional investors. 2.9% of VistaGen Therapeutics shares are owned by insiders. Comparatively, 17.6% of Madrigal Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares VistaGen Therapeutics and Madrigal Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
VistaGen Therapeutics	-2,702.64%	-152.59%	-117.45%
Madrigal Pharmaceuticals	-10.89%	-27.08%	-12.04%

Analyst Recommendations

This is a summary of recent ratings for VistaGen Therapeutics and Madrigal Pharmaceuticals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
VistaGen Therapeutics	1	4	0	0	1.80
Madrigal Pharmaceuticals	1	2	13	1	2.82

VistaGen Therapeutics currently has a consensus target price of $0.95, suggesting a potential upside of 479.98%. Madrigal Pharmaceuticals has a consensus target price of $706.87, suggesting a potential upside of 76.88%. Given VistaGen Therapeutics’ higher probable upside, analysts clearly believe VistaGen Therapeutics is more favorable than Madrigal Pharmaceuticals.

Valuation and Earnings

This table compares VistaGen Therapeutics and Madrigal Pharmaceuticals”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
VistaGen Therapeutics	$2.50 million	2.91	-$69.68 million	($1.66)	-0.10
Madrigal Pharmaceuticals	$1.43 billion	6.50	-$288.28 million	($5.98)	-66.83

VistaGen Therapeutics has higher earnings, but lower revenue than Madrigal Pharmaceuticals. Madrigal Pharmaceuticals is trading at a lower price-to-earnings ratio than VistaGen Therapeutics, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

VistaGen Therapeutics has a beta of 0.49, suggesting that its share price is 51% less volatile than the S&P 500. Comparatively, Madrigal Pharmaceuticals has a beta of -0.98, suggesting that its share price is 198% less volatile than the S&P 500.

Summary

Madrigal Pharmaceuticals beats VistaGen Therapeutics on 10 of the 15 factors compared between the two stocks.

About VistaGen Therapeutics

Vistagen Therapeutics, Inc., a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines. Its product pipeline comprises PH94B, a fasedienol nasal spray, which is in Phase III development for the treatment of social anxiety disorder; and PH10, a Ituvone nasal spray which is in Phase II development for the treatment of major depressive disorder. In addition, the company is also developing PH15, an early-stage investigational synthetic neuroactive steroid for the treatment of cognition improvement; PH80, an odorless and tasteless synthetic investigational pherine for the treatment of menopausal hot flashes and migraine; PH284, an early-stage investigational synthetic neuroactive steroid for the treatment of wasting syndrome Cachexia; and AV-101, an oral nmdr glycine site antagonist for depression and neurological disorders. Further, it has a license and collaboration agreement with EverInsight Therapeutics Inc. to develop and commercialize to address ophthalmologic and CNS disorders. The company was founded in 1998 and is headquartered in South San Francisco, California.

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.